Ebola in Africa
Ebola is the name of a particularly aggressive virus capable of producing potentially fatal hemorrhagic fever in humans and other primates (monkeys, gorillas, and chimps); the virus was discovered in 1976 in Congo (Africa).
It is a dangerous and frequently fatal disease that can be passed from person to person through direct contact with an infected patient's blood or secretions.
Origination of Ebola
The exact origins of the infection are unknown, but Guinean health officials connected the epidemic to the funeral of a nurse in early February in Goueké, near the southeastern town of Zerecoré.
The funeral was attended by all seven afflicted individuals. They later complained of diarrhea, vomiting, and bleeding. At least three of these people were killed. The others remain hospitalized.
In West Africa, traditional funerals are often the scene of community ceremonies where those present help wash the dead’s body. This can be especially dangerous if the corpse is infected with Ebola. The incubation period for the disease can last from two days to three weeks.
The outbreak in Guinea comes a week after the Democratic Republic of Congo (DRC) confirmed two Ebola deaths - three months after the Central African nation declared the end of an epidemic that spanned about half a year in 2020. , and which claimed 55 lives among 130 cases of infection. So far, the cases in Guinea and Congo do not appear to be related.
Symptoms of Ebola
• fever,
• headache,
• joint and muscle pain,
• weakness,
• diarrhea,
• A stomach ache,
• lack of appetite.
Other symptoms may also occur including
• rash cutaneo,
• Red eyes
• and internal and external bleeding (hemorrhages).
The first symptoms with which the infection occurs are similar to other more common diseases and this makes a timely diagnosis difficult, which is usually confirmed through specific laboratory tests.
There is no specific cure, the treatment, therefore, includes supportive therapies such as
• fluids,
• oxygen
• and treatment of complications.
Considering overall the high mortality, the rapidity with which symptoms appear, and the localization of infections (usually isolated regions), the risk of a global epidemic is considered low; however, the virus could potentially be used as a biological weapon.
Ebola Virus
The virus has some animal species as its main reservoir, the bat seems to be the main one, and human beings can contract the virus from infected animals (which is confirmed to be absent in Italy ).
After initial transmission, viruses can spread from person to person through contact with contaminated body fluids or needles.
How Ebola Spread?
Since the main reservoir has not yet been proven with certainty, how the first human subject is affected has not yet been clarified, but it is speculated that it is through contact with an infected animal.
From animals to man
The virus could be transmitted to humans by exposure to the body fluids of an infected animal:
Blood: The slaughter or consumption of infected animals can spread the virus. Scientists who operated on infected animals contracted the virus as part of their research.
Waste products. Tourists of some African caves and some workers in mines have been infected with the Marburg virus, a similar virus, probably by contact with the feces or urine of infected bats.
From person to person
Infected people typically don't become contagious until they develop symptoms.
There is no evidence that the Ebola virus can be spread via insect bites.
When Ebola infection occurs in humans there are several ways the virus can be passed on to other men and women:
direct contact with fluids and secretions of an infected person (saliva, blood, sweat, feces, urine, vomit, semen, ...),
exposure to objects (such as needles) that have been contaminated with infected secretions.
The viruses that cause the disease find it easy to spread in families and groups of friends as they are subjects who come into close contact with the infecting secretions when caring for the sick. During outbreaks (i.e. small epidemics) the disease can spread rapidly even within health facilities (such as clinics and hospitals) if the staff does not wear adequate protective equipment such as masks, gowns, and gloves. Medical centers in Africa are often so poor that they have to reuse needles and syringes, and some of the worst Ebola outbreaks have occurred due to contaminated injections.
The contagiousness lasts as long as blood, secretions, organs, or semen contain the virus: Ebola virus has been isolated from sperm up to months after the onset of the disease, and transmission through sperm has been ascertained 7 weeks after clinical recovery (source: Safe Travel ).
Food and more
The Ebola virus does not spread through the air, water, or even food, although in reality there may have been cases of contagion in Africa due to the careless handling of the meat of wild animals that have come into contact with infected bats.
There is no evidence that mosquitoes or other insects can transmit the Ebola virus, and only a few mammal species (e.g. humans, bats, and monkeys) have demonstrated the ability to be infected with the Ebola virus.
Symptoms
The US CDC has reported the following criteria for identifying patients at risk:
Clinical criteria, including
• fever above 38.6 ° C,
• headache,
• muscle aches,
• diarrhea,
• abdominal pain,
• unexplained bleeding.
Epidemiological risk factors in the last 21 days before symptoms appear, such as
contact with the blood or other bodily fluids or human remains of a patient known to have or suspected of having the infection;
residence or origin from an affected area,
direct handling of bats or non-human primates from disease-endemic areas.
In the absence of both these conditions there is no reason to fear contagion, but let's see specifically the main symptoms of the disease.
The average incubation time is about 8-12 days, but it can vary from 2 to 21, while the average interval between the onset of the first symptoms and death varies from 3 to 21 days, with an average of about 10 days.
The first symptoms that appear in the case of Ebola are:
• fever (87% of patients),
• sore throat,
• skin rash (more visible in fair-skinned patients),
• red eyes and conjunctivitis,
• chills,
• joint and muscle pain,
• malaise,
• weakness (76% of patients).
Gastrointestinal symptoms may appear after about 5 days:
• watery diarrhea (66% of patients),
• nausea and vomiting (68% of patients),
• stomach pain,
• abdominal pain,
• loss of appetite (65% of patients).
and other symptoms such as
• chest pain,
• shortness of breath
• headache,
• confusion.
Some patients may also experience:
• hiccups,
• cough,
• convulsions,
• weight loss,
• difficulty swallowing,
• bleeding ( bleeding inside and outside the body).
Hemorrhage is not always present but can manifest itself in a second phase in the form of petechiae, bruising / hematoma, unjustified bleeding following injections.
In patients who will die, more severe clinical signs usually develop from the first days; on the contrary, in cases of recovery, patients may have a fever for several days and improve, usually around day 6, although they still need a prolonged convalescence.
Mortality among patients in West Africa in the epidemic that began in 2014 is about 71% (range from 46% in Nigeria to 69-72% in Guinea, Sierra Leone, and Liberia); risk factors significantly associated with a fatal outcome in affected African countries are:
• age over 45,
• unexplained bleeding,
• several other signs and symptoms that are not all common:
• diarrhea,
• chest pain,
• cough,
• respiratory difficulties,
• difficulty swallowing,
• conjunctivitis,
• sore throat,
• confusion,
• hiccup,
• coma or unconsciousness.
Unfortunately, pregnant women are usually subject to spontaneous abortion.
For people who survive, recovery is slow, it can take months to regain weight and strength, and the virus remains in the body for many months.
Dangers
According to the viral strain, the mortality rate is extremely high, ranging from 50 to 89%.
As the disease progresses it can cause:
• failure of several organs,
• severe bleeding,
• jaundice,
• delirium,
• convulsions,
• shock.
Finally, researchers have identified the so-called post-ebola viral syndrome, a condition capable of affecting a patient who has survived the infection and which manifests itself with the appearance of symptoms such as:
• joint pain,
• muscular pain,
• eye problems (in some cases blindness),
• neurological disorders,
• severe fatigue,
• hearing loss
• hair loss,
• changes in the menstrual cycle,
• long-term worsening of general health.
• Diagnosis
Early diagnosis of the disease is difficult because early symptoms such as red eyes and skin rash are non-specific and are often seen in patients with more common diseases.
Laboratory tests used in diagnosis include:
Within a few days after the symptoms begin
• ELISA test (Enzyme-Linked ImmunoSorbent Assay)
• IgM
• PCR
• Virus isolation
Later in the course of the illness or after hospitalization
• IgM and IgG antibodies
• In deceased patients
• Immunohistochemistry test
• PCR
• Virus isolation
Cure to Ebola || Treatment and therapy
The standard treatment for Ebola is unfortunately limited only to patient support and symptom management, as there are currently no specific drugs, through
administration of fluids and electrolytes via drip,
constant maintenance of the state of oxygenation and blood pressure, possibly also with transfusions,
treating any over-infections.
Early treatment is important, but unfortunately not easy as early diagnosis is not always possible.
Prevention of Ebola
Disease prevention presents many challenges; since the exact path of contagion is still unknown, some guidelines have been developed for health personnel to be adopted when the first cases appear, but in fact, isolation of the patient is essential to safeguard family and friends.
Also worth remembering for travelers:
• Avoid traveling to areas of known outbreaks.
• Wash your hands frequently, using soap and water or products containing at least 60 percent alcohol.
• Avoid bushmeat in developing countries.
• Avoid contact with infected people.
• Do not handle the remains of patients who have died of Ebola.
Vaccine for Ebola
On 11 November 2019, the first vaccine against Ebola was authorized for marketing, with the trade name Ervebo (produced by Merck Sharp & Dohme BV) and understudy since 2014 (the year of the most serious epidemic. never recorded in recent age).
This is a conditional authorization, which made it possible to adopt a more streamlined procedure than normal, by the pressing need to find an effective preventive solution to the emergency linked to the epidemic; this possibility is reserved for specific cases, where the advantage of immediate availability outweighs the risk associated with the availability of still incomplete data (generally speaking, therefore, of medicines aimed at treating, preventing or diagnosing seriously debilitating or life-threatening diseases).
In other words, the vaccine is still considered to be tested (in Congo, where the current mortality rate linked to the infection is about 67%), but according to the WHO it is considered sufficiently effective and safe to be able to enjoy a wider use; the current data speaking of efficacy in immunization equal to 97.5% of vaccinated patients.
Current information identifies classic reactions to injectable vaccines, such, as the most common side effects
• pain, swelling, and erythema at the injection site,
• headache,
• fever,
• muscle and joint pain,
• fatigue.
A second vaccine, made by Johnson & Johnson, was approved in July 2020 and several others are under study.